[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100053403":3},{"organization":4,"outcomesModule":7,"designInfo":53,"detailedDescription":34,"studyPopulation":34,"armGroups":62,"interventions":74,"overallOfficials":84,"centralContacts":91,"locations":97,"responsibleParty":112,"collaborators":34,"id":114,"slug":34,"hasResults":115,"nctId":116,"briefTitle":117,"officialTitle":118,"acronym":34,"eligibilityCriteria":119,"healthyVolunteers":120,"sex":121,"minAge":122,"maxAge":123,"enrollmentInfo":124,"targetDuration":34,"studyType":127,"phases":128,"briefSummary":130,"conditions":131,"keywords":34,"overallStatus":133,"whyStopped":34,"lastUpdateSubmitDate":134,"lastUpdatePostDateStruct":135,"startDateStruct":138,"completionDateStruct":140,"leadSponsor":142,"locationsCount":143},{"fullName":5,"class":6},"Beijing QL Biopharmaceutical Co.,Ltd","INDUSTRY",{"primaryOutcomes":8,"secondaryOutcomes":13,"otherOutcomes":34},[9],{"measure":10,"description":11,"timeFrame":12},"Change to baseline- and placebo-corrected QTc interval (ΔΔQTc)","Effect of ZT002 plasma concentrations on the ΔΔQTc interval using linear mixed effect exposure-response modeling.","Up to Day 141",[14,17,20,23,26,29,32,35,37,39,41,43,45,47,49,51],{"measure":15,"description":16,"timeFrame":12},"Effect of ZT002 plasma concentrations on heart rate (HR)","Measure the Effect of ZT002 plasma concentrations on HR",{"measure":18,"description":19,"timeFrame":12},"Effect of ZT002 plasma concentrations on QT interval corrected using Fridericia's formula (QTcF)","Measure the Effect of ZT002 plasma concentrations on QTcF;",{"measure":21,"description":22,"timeFrame":12},"Effect of ZT002 plasma concentrations on PR interval","Measure the Effect of ZT002 plasma concentrations on PR interval",{"measure":24,"description":25,"timeFrame":12},"Effect of ZT002 plasma concentrations on QRS complex duration","Measure the Effect of ZT002 plasma concentrations on QRS complex duration",{"measure":27,"description":28,"timeFrame":12},"Effect of ZT002 plasma concentrations on T wave","Measure the Effect of ZT002 plasma concentrations on T wave",{"measure":30,"description":31,"timeFrame":12},"Effect of ZT002 plasma concentrations on U wave","Measure the Effect of ZT002 plasma concentrations on U wave",{"measure":33,"description":34,"timeFrame":12},"PK parameter analysis of ZT002 for area under cure from time zero to 72 hours (AUC0-72h)",null,{"measure":36,"description":34,"timeFrame":12},"PK parameter analysis of ZT002 for peak concentration (Cmax)",{"measure":38,"description":34,"timeFrame":12},"PK parameter analysis of ZT002 for time to peak concentration (Tmax)",{"measure":40,"description":34,"timeFrame":12},"Incident of anti-drug antibody against ZT002",{"measure":42,"description":34,"timeFrame":12},"Incidence of adverse events (AEs)",{"measure":44,"description":34,"timeFrame":12},"Change in body weight (kg)",{"measure":46,"description":34,"timeFrame":12},"Change in Body Mass Index (BMI) (kg\u002Fm²)",{"measure":48,"description":34,"timeFrame":12},"Change in waist circumference (cm)",{"measure":50,"description":34,"timeFrame":12},"Change in hip circumference (cm)",{"measure":52,"description":34,"timeFrame":12},"Change in serum lipid concentrations (high-density lipoprotein cholesterol, low-density lipoprotein cholesterol, total cholesterol, triglycerides) (%)",{"allocation":54,"interventionModel":55,"interventionModelDescription":34,"primaryPurpose":56,"observationalModel":34,"timePerspective":34,"maskingInfo":57},"RANDOMIZED","PARALLEL","TREATMENT",{"masking":58,"maskingDescription":34,"whoMasked":59},"DOUBLE",[60,61],"PARTICIPANT","INVESTIGATOR",[63,69],{"label":64,"type":65,"description":66,"interventionNames":67},"cohort1 ZT002 injection","EXPERIMENTAL","Participants will receive 8 study interventions. The study interventions will be administered during treatment periods starting on Days 1, 15, 29, 43, 57, 71, 85 and 99.",[68],"Drug: ZT002 injection",{"label":70,"type":65,"description":71,"interventionNames":72},"cohort2 ZT002 injection matching placebo","Participants will receive 8 matching placebo interventions. The interventions will be administered during treatment periods starting on Days 1, 15, 29, 43, 57, 71, 85 and 99.",[73],"Drug: ZT002 injection matching placebo",[75,80],{"type":76,"name":77,"description":78,"armGroupLabels":79,"otherNames":34},"DRUG","ZT002 injection","Subjects will receive subcutaneous injections of Zovaglutide (ZT002 Injection) once every two weeks.",[64],{"type":76,"name":81,"description":82,"armGroupLabels":83,"otherNames":34},"ZT002 injection matching placebo","Subjects will receive subcutaneous injections of ZT002 injection matching placebo once every two weeks.",[70],[85,89],{"name":86,"affiliation":87,"role":88},"Quankun Zhuang, Doctor","Beijing GoBroad Hospital","PRINCIPAL_INVESTIGATOR",{"name":90,"affiliation":87,"role":88},"Xuemei Liu, Doctor",[92],{"name":93,"role":94,"phone":95,"phoneExt":34,"email":96},"Li Liu","CONTACT","+86-13911711598","liu.li@qlbiopharm.com",[98],{"facility":87,"status":34,"city":99,"state":34,"zip":100,"country":101,"countryCode":102,"cosmosGeoPoint":103,"geoPoint":108,"contacts":109},"Beijing","102200","China","CN",{"type":104,"coordinates":105},"Point",[106,107],116.39723,39.9075,{"lat":107,"lon":106},[110],{"name":111,"role":94,"phone":34,"phoneExt":34,"email":34},"Quankun Zhuang, Master",{"type":113,"investigatorFullName":34,"investigatorTitle":34,"investigatorAffiliation":34,"oldNameTitle":34,"oldOrganization":34},"SPONSOR","100053403",false,"NCT07697846","A Study to Investigate the Effects of Zovaglutide (ZT002 Injection) on QTc Interval in Healthy Adults","Phase 1, Single-Center, Randomized, Double-Blind, Parallel-Group Placebo-Controlled（Concentration）-QTc（C-QTc）Study to Evaluate the Impact of ZT002 Injection on QTc Interval in Chinese Overweight and Obese Subjects","Inclusion Criteria:\n\n* Ability to understand the trial procedures and possible adverse events, be able and willing to provide a written informed consent;\n* Age between 18 - 45 years (both inclusive) at the time of signing of the informed consent;\n* Male (body weight \\>60.0 kg) or female (body weight \\>55.0 kg). Body mass index (BMI) 24.0 - 35.0 kg\u002Fm²(both inclusive);\n\nExclusion Criteria:\n\n* Known hypersensitivity (asthma, hypersensitivity to GLP-1 receptor agonists or excipients), or known hypersensitivity to ZT002 injection;\n* History of acute or chronic pancreatitis, or pancreatic injury.History of medullary thyroid carcinoma (MTC) or type 2 multiple endocrine neoplasia (MEN2) in personal or family history.\n* Has a history of cardiovascular diseases or risk factors predisposing to torsades de pointes (TdP); has personal or family history of any cardiac conduction abnormalities; has personal or family history of long QT syndrome (LQTS); or has a family history of sudden cardiac death.\n* Those with any type of malignant tumors within 5 years prior to screening (except cured basal cell carcinoma of the skin or carcinoma in situ of the cervix).\n* Medical history of hypoglycemia within 6 months before screening;\n* History of acute or chronic pancreatitis;\n* ECG findings exceeding thresholds at screening or prior to randomization: PR interval \\>220 ms, QRS duration \\>110 ms, heart rate (HR) \\\u003C50 bpm or \\>100 bpm, QTcF ≥450 ms; or presence of any ECG abnormalities deemed clinically significant by the investigator.\n* Glycated hemoglobin (HbA1c) ≥ 6.5% or fasting plasma glucose ≥ 7.0 mmol\u002FL at screening;\n* Aspartate aminotransferase \\> 2 × upper limit of normal (ULN), Alanine aminotransferase \\> 2 × ULN,\n* Alkaline phosphatase total bilirubin \\> 1.5 × ULN;\n* Subjects who have previously undergone gastric bariatric surgery or other weight-loss surgeries, or who plan to receive weight-loss surgery, liposuction, abdominal lipectomy, or other procedures with substantial impacts on body weight during the study.\n* Use of weight-altering medications or therapies within 3 months prior to screening.\n* Administration of any medications known to prolong QT\u002FQTc interval, alter heart rate, or carry risks of torsades de pointes (TdP) within 4 weeks prior to screening\n* Pregnant or lactating women, or subjects with a positive pregnancy test result at screening\u002Fbaseline",true,"ALL","18 Years","45 Years",{"count":125,"type":126},40,"ESTIMATED","INTERVENTIONAL",[129],"PHASE1","This study is designed to investigate the effect of treatment with Zovaglutide (ZT002 Injection) on the corrected cardiac QT interval relative to a placebo control in healthy participants.",[132],"Overweight, Obesity","NOT_YET_RECRUITING","2026-07-06",{"date":136,"type":137},"2026-07-13","ACTUAL",{"date":139,"type":126},"2026-07-18",{"date":141,"type":126},"2027-03-24",{"name":5,"class":6},1]